PL2531027T3 - Kombinacja terapeutyczna zawierająca dolutegrawir, abakawir i lamiwudynę - Google Patents

Kombinacja terapeutyczna zawierająca dolutegrawir, abakawir i lamiwudynę

Info

Publication number: PL2531027T3
Authority: PL; Poland
Prior art keywords: dolutegravir; abacavir; lamivudine; therapeutic combination; therapeutic
Prior art date: 2010-01-27

Application number

PL11737484T

Other languages

English (en)

Inventor

Mark Richard Underwood

Original Assignee

Viiv Healthcare Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-27

Filing date

2011-01-24

Publication date

2016-01-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2531027(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-01-24 Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co

2016-01-29 Publication of PL2531027T3 publication Critical patent/PL2531027T3/pl

Links

UGWQMIXVUBLMAH-IVVFTGHFSA-N [(1s,4r)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol;4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 UGWQMIXVUBLMAH-IVVFTGHFSA-N 0.000 title 1
RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 title 1
229960002542 dolutegravir Drugs 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

PL11737484T 2010-01-27 2011-01-24 Kombinacja terapeutyczna zawierająca dolutegrawir, abakawir i lamiwudynę PL2531027T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US29858910P	2010-01-27	2010-01-27
EP11737484.3A EP2531027B1 (en)	2010-01-27	2011-01-24	Therapeutic combination comprising dolutegravir, abacavir and lamivudine
PCT/US2011/022219 WO2011094150A1 (en)	2010-01-27	2011-01-24	Antiviral therapy

Publications (1)

Publication Number	Publication Date
PL2531027T3 true PL2531027T3 (pl)	2016-01-29

Family

ID=44319704

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL16187411T PL3127542T3 (pl)	2010-01-27	2011-01-24	Terapia przeciwwirusowa
PL11737484T PL2531027T3 (pl)	2010-01-27	2011-01-24	Kombinacja terapeutyczna zawierająca dolutegrawir, abakawir i lamiwudynę
PL15164931T PL2932970T3 (pl)	2010-01-27	2011-01-24	Terapia antywirusowa

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL16187411T PL3127542T3 (pl)	2010-01-27	2011-01-24	Terapia przeciwwirusowa

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL15164931T PL2932970T3 (pl)	2010-01-27	2011-01-24	Terapia antywirusowa

Country Status (45)

Country	Link
US (12)	US20120295898A1 (pl)
EP (6)	EP2531027B1 (pl)
JP (8)	JP2013518107A (pl)
KR (4)	KR101830715B1 (pl)
CN (2)	CN102791129B (pl)
AP (1)	AP3551A (pl)
AU (1)	AU2011209788C1 (pl)
BR (1)	BR112012018670A2 (pl)
CA (4)	CA3003988C (pl)
CL (1)	CL2012002080A1 (pl)
CO (1)	CO6602152A2 (pl)
CR (1)	CR20120423A (pl)
CY (4)	CY1116509T1 (pl)
DK (4)	DK3127542T3 (pl)
DO (2)	DOP2012000205A (pl)
EA (4)	EA032868B1 (pl)
EC (1)	ECSP12012106A (pl)
ES (4)	ES2969969T3 (pl)
FI (1)	FI3494972T3 (pl)
FR (1)	FR18C1043I2 (pl)
HK (3)	HK1179522A1 (pl)
HR (4)	HRP20240168T1 (pl)
HU (4)	HUE037812T2 (pl)
IL (5)	IL221007A (pl)
LT (4)	LT2932970T (pl)
LU (1)	LUC00090I2 (pl)
MA (1)	MA34002B1 (pl)
ME (2)	ME03058B (pl)
MX (4)	MX356891B (pl)
MY (1)	MY188334A (pl)
NO (2)	NO2932970T3 (pl)
NZ (4)	NZ627824A (pl)
PE (2)	PE20160180A1 (pl)
PH (2)	PH12016500195A1 (pl)
PL (3)	PL3127542T3 (pl)
PT (4)	PT2531027E (pl)
RS (4)	RS65183B1 (pl)
SG (3)	SG182614A1 (pl)
SI (4)	SI3494972T1 (pl)
SM (1)	SMT201500177B (pl)
TN (1)	TN2012000376A1 (pl)
TR (1)	TR201807704T4 (pl)
UA (1)	UA105556C2 (pl)
WO (1)	WO2011094150A1 (pl)
ZA (1)	ZA201205586B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2531027E (pt)	2010-01-27	2015-09-16	Viiv Healthcare Co	Combinação terapêutica compreendendo dolutegravir, abacavir e lamivudina
CA2885763C (en)	2012-10-23	2021-04-06	Cipla Limited	Pharmaceutical antiretroviral composition
CA3012242C (en)	2012-12-21	2021-11-02	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2767272A1 (en) *	2013-02-18	2014-08-20	Ratiopharm GmbH	Solid pharmaceutical dosage form of dolutegravir
EP2956123A1 (en) *	2013-02-18	2015-12-23	ratiopharm GmbH	Solid pharmaceutical dosage form of dolutegravir
AU2014286993B2 (en)	2013-07-12	2018-10-25	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections
NO2865735T3 (pl)	2013-07-12	2018-07-21
WO2015048363A1 (en)	2013-09-27	2015-04-02	Merck Sharp & Dohme Corp.	Substituted quinolizine derivatives useful as hiv integrase inhibitors
IN2014MU00916A (pl)	2014-03-20	2015-09-25	Cipla Ltd
JP6768522B2 (ja)	2014-06-04	2020-10-14	サンフォード−バーンハムメディカルリサーチインスティテュート	Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
TWI744723B (zh)	2014-06-20	2021-11-01	美商基利科學股份有限公司	多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (pl)	2014-06-20	2018-06-23
TW201613936A (en)	2014-06-20	2016-04-16	Gilead Sciences Inc	Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
EP3177629B1 (en)	2014-07-29	2020-01-29	LEK Pharmaceuticals d.d.	Novel hydrates of dolutegravir sodium
TWI695003B (zh)	2014-12-23	2020-06-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3277691B1 (en)	2015-04-02	2019-01-30	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3334419A1 (en) *	2015-08-14	2018-06-20	Sandoz AG	Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) *	2016-05-27	2017-11-30	Viiv Healthcare Company	Combinations and uses treatments thereof
WO2018028841A1 (en) *	2016-08-12	2018-02-15	Sandoz Ag	Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) *	2016-08-31	2018-03-08	Glaxosmithkline Intellectual Property (No.2) Limited	Combinations and uses and treatments thereof
JP2020527570A (ja) *	2017-07-18	2020-09-10	ヴィーブヘルスケアカンパニー	組み合わせ薬物療法
JP2020528413A (ja) *	2017-07-21	2020-09-24	ヴィーブヘルスケアカンパニー	Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
MX2020000790A (es)	2017-07-21	2020-11-11	Viiv Healthcare Co	Pautas para el tratamiento de infecciones por el vih y sida.
WO2019074826A2 (en) *	2017-10-13	2019-04-18	Viiv Healthcare Company	FORMULATION OF BICOLET PHARMACEUTICAL TABLET
BR112021018827A2 (pt)	2019-03-22	2021-11-23	Gilead Sciences Inc	Compostos de carbamoilpiridona tricíclica em ponte e seu uso farmacêutico
BR112022013452A2 (pt) *	2020-01-09	2022-09-13	Univ Washington	Combinações de agentes terapêuticos de ação prolongada e métodos das mesmas
EP4110783A1 (en)	2020-02-24	2023-01-04	Gilead Sciences, Inc.	Tetracyclic compounds for treating hiv infection
HUE064467T2 (hu)	2021-01-19	2024-03-28	Gilead Sciences Inc	Szubsztituált piridotriazin-származékok és alkalmazásuk
WO2023164293A1 (en) *	2022-02-28	2023-08-31	Jericho Sciences, Llc	Methods for viral infections

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en)	1989-02-08	2006-10-10	Glaxo Wellcome Inc.	Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
GB8815265D0 (en)	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
GB9009861D0 (en)	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
ZA923640B (en)	1991-05-21	1993-02-24	Iaf Biochem Int	Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en)	1991-06-03	1991-07-24	Glaxo Group Ltd	Chemical compounds
GB9204015D0 (en)	1992-02-25	1992-04-08	Wellcome Found	Therapeutic nucleosides
US5519021A (en)	1992-08-07	1996-05-21	Merck & Co., Inc.	Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en)	1992-08-07	1997-11-20	Merck & Co Inc	Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en)	1994-02-04	1994-03-30	Wellcome Found	Chloropyrimidine intermediates
IL113432A (en)	1994-04-23	2000-11-21	Glaxo Group Ltd	Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk)	1994-06-03	2002-10-15	Дж.Д. Сьорль Енд Ко	Спосіб лікування ретровірусних інфекцій
MY115461A (en)	1995-03-30	2003-06-30	Wellcome Found	Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en)	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
US5849911A (en)	1996-04-22	1998-12-15	Novartis Finance Corporation	Antivirally active heterocyclic azahexane derivatives
US6544961B1 (en) *	1996-06-25	2003-04-08	Smithkline Beecham Corporation	Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatments of HIV
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en)	1997-02-05	1999-10-12	Merck & Co., Inc.	Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en)	1997-05-17	1997-07-09	Glaxo Group Ltd	A novel salt
US5935946A (en)	1997-07-25	1999-08-10	Gilead Sciences, Inc.	Nucleotide analog composition and synthesis method
GB9717928D0 (en)	1997-08-22	1997-10-29	Glaxo Group Ltd	Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en)	1997-10-14	1997-12-10	Glaxo Group Ltd	Process for the synthesis of chloropurine intermediates
US6436989B1 (en)	1997-12-24	2002-08-20	Vertex Pharmaceuticals, Incorporated	Prodrugs of aspartyl protease inhibitors
US6087383A (en)	1998-01-20	2000-07-11	Bristol-Myers Squibb Company	Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en)	1998-03-20	1998-05-13	Glaxo Group Ltd	Process for the sythesis of hiv protease inhibitors
WO1999048371A1 (en)	1998-03-27	1999-09-30	The Regents Of The University Of California	Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk)	1998-04-07	2005-02-15	Брістол- Майєрс Сквібб Фарма Компані	Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) *	1998-04-29	1998-07-01	Glaxo Group Ltd	Pharmaceutical compositions
GB9815567D0 (en)	1998-07-18	1998-09-16	Glaxo Group Ltd	Antiviral compound
MXPA02007426A (es)	2000-01-31	2003-10-14	Cook Biotech Inc	Valvulas restringidas y uso de las mismas.
HU229025B1 (en)	2001-04-10	2013-07-29	Pfizer	Pyrazole derivatives for treating hiv, pharmaceutical compositions containing them and process for their preparation
US7638522B2 (en) *	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) *	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
TW200403061A (en) *	2002-06-04	2004-03-01	Glaxo Group Ltd	Pharmaceutical compositions
CN1302779C (zh)	2002-06-27	2007-03-07	美迪维尔公司	含有阿巴卡韦和阿洛夫定的药物制剂及其用途
US20040224916A1 (en) *	2003-01-14	2004-11-11	Gilead Sciences, Inc.	Compositions and methods for combination antiviral therapy
TW200510425A (en)	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
KR20070002006A (ko) *	2004-02-11	2007-01-04	스미스클라인 비참 코포레이션	Ｈｉｖ 인테그라제 억제제
US20080076738A1 (en) *	2004-04-14	2008-03-27	Cai Zhenhong R	Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds
WO2005112930A1 (en) *	2004-05-21	2005-12-01	Japan Tobacco Inc.	Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
US7176196B2 (en)	2004-05-28	2007-02-13	Bristol-Myers Squibb Company	Bicyclic heterocycles as HIV integrase inhibitors
ATE495747T1 (de)	2004-08-23	2011-02-15	Teva Pharma	Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
KR101284361B1 (ko)	2004-09-02	2013-07-15	얀센 파마슈티카 엔.브이.	4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
EP2256124A1 (en)	2004-09-17	2010-12-01	IDENIX Pharmaceuticals, Inc.	Phospho-indoles as HIV inhibitors
JP2008531716A (ja)	2005-03-04	2008-08-14	スミスクラインビーチャムコーポレーション	化合物
CN101212903B (zh) *	2005-04-28	2013-07-24	史密丝克莱恩比彻姆公司	具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
PL3284520T3 (pl) *	2005-04-28	2020-01-31	Viiv Healthcare Company	Policykliczna pochodna karbamoilopirydonu mająca aktywność hamowania integrazy HIV
CN101336107A (zh) *	2005-12-30	2008-12-31	吉里德科学公司	改善hiv整合酶抑制剂的药物动力学的方法
WO2007079260A1 (en)	2005-12-30	2007-07-12	Gilead Sciences, Inc.	Methods for improving the pharmacokinetics of hiv integrase inhibitors
KR101501475B1 (ko) *	2006-01-20	2015-03-19	얀센 알 앤드 디 아일랜드	Ｔｍｃ２７８을 이용한 ｈｉｖ 감염의 장기간 요법
US20080039428A1 (en)	2006-06-29	2008-02-14	Panacos Pharmaceuticals, Inc.	Antiretroviral combination therapy
NZ573887A (en)	2006-07-21	2012-02-24	Gilead Sciences Inc	Antiviral protease inhibitors
EP2078029B1 (en)	2006-09-29	2014-05-14	IDENIX Pharmaceuticals, Inc.	Enantiomerically pure phosphoindole as hiv inhibitor
WO2008103899A1 (en)	2007-02-23	2008-08-28	Auspex Pharmaceuticals, Inc.	Preparation and utility of non-nucleoside reverse transcriptase inhibitors
PT2487166T (pt)	2007-02-23	2016-10-17	Gilead Sciences Inc	Moduladores de propriedades farmacocinéticas de agentes terapêuticos
US8354421B2 (en)	2007-06-29	2013-01-15	Korea Research Insitute Of Chemical Technology	HIV reverse transcriptase inhibitors
MX2009013804A (es)	2007-06-29	2010-02-03	Korea Res Inst Chem Tech	Inhibidores novedosos de transcriptasa inversa de vih.
CN101796040A (zh)	2007-07-06	2010-08-04	吉里德科学公司	治疗剂的药代动力学特性调节剂
EP2175857B1 (en) *	2007-07-12	2013-09-11	Janssen R&D Ireland	Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
WO2009058923A1 (en)	2007-10-31	2009-05-07	Smithkline Beecham Corporation	Ccr5 antagonists as therapeutic agents
US8466177B2 (en)	2007-11-01	2013-06-18	The Uab Research Foundation	Treating and preventing viral infections
US8108055B2 (en)	2007-12-28	2012-01-31	Larry Wong	Method, system and apparatus for controlling an electrical device
WO2009082818A1 (en)	2008-01-03	2009-07-09	Virochem Pharma Inc.	Novel c-21-keto lupane derivatives preparation and use thereof
CA2711424A1 (en) *	2008-01-03	2009-07-09	Virochem Pharma Inc.	Novel lupane derivatives
US8759379B2 (en)	2008-01-04	2014-06-24	Gilead Sciences, Inc.	Inhibitors of cytochrome P450
AU2009214779A1 (en)	2008-02-14	2009-08-20	Virochem Pharma Inc.	Novel 17beta lupane derivatives
WO2009148600A2 (en) *	2008-06-06	2009-12-10	Concert Pharmaceuticals, Inc.	Deuterated lysine-based compounds
PL2320908T3 (pl) *	2008-07-25	2014-06-30	Viiv Healthcare Co	Proleki dolutegrawiru
RU2527451C2 (ru) *	2008-12-11	2014-08-27	Вайв Хелткер Компани	Синтез карбамоилпиридоновых ингибиторов интегразы вич и промежуточных соединений
CN104788367A (zh)	2008-12-11	2015-07-22	盐野义制药株式会社	氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
PT2531027E (pt)	2010-01-27	2015-09-16	Viiv Healthcare Co	Combinação terapêutica compreendendo dolutegravir, abacavir e lamivudina
GB201006038D0 (en)	2010-04-12	2010-05-26	Unilever Plc	Improvements relating to antiviral compositions
EP2590971A4 (en)	2010-06-17	2014-12-10	Fuzians Biomedicals Inc	COMPOUNDS USEFUL AS ANTIVIRAL AGENTS, COMPOSITIONS, AND METHODS OF USE

2011
- 2011-01-24 PT PT117374843T patent/PT2531027E/pt unknown
- 2011-01-24 TR TR2018/07704T patent/TR201807704T4/tr unknown
- 2011-01-24 MX MX2014014689A patent/MX356891B/es unknown
- 2011-01-24 EP EP11737484.3A patent/EP2531027B1/en not_active Revoked
- 2011-01-24 PL PL16187411T patent/PL3127542T3/pl unknown
- 2011-01-24 CA CA3003988A patent/CA3003988C/en active Active
- 2011-01-24 EP EP23214771.0A patent/EP4316599A3/en active Pending
- 2011-01-24 US US13/575,380 patent/US20120295898A1/en not_active Abandoned
- 2011-01-24 PT PT191518976T patent/PT3494972T/pt unknown
- 2011-01-24 CA CA2967453A patent/CA2967453C/en active Active
- 2011-01-24 CN CN201180015114.8A patent/CN102791129B/zh active Active
- 2011-01-24 HU HUE15164931A patent/HUE037812T2/hu unknown
- 2011-01-24 MX MX2012008774A patent/MX2012008774A/es active IP Right Grant
- 2011-01-24 MY MYPI2012003346A patent/MY188334A/en unknown
- 2011-01-24 SG SG2012053492A patent/SG182614A1/en unknown
- 2011-01-24 RS RS20240189A patent/RS65183B1/sr unknown
- 2011-01-24 PL PL11737484T patent/PL2531027T3/pl unknown
- 2011-01-24 ME MEP-2018-131A patent/ME03058B/me unknown
- 2011-01-24 DK DK16187411.0T patent/DK3127542T3/en active
- 2011-01-24 EP EP15164931.6A patent/EP2932970B1/en not_active Revoked
- 2011-01-24 ES ES19151897T patent/ES2969969T3/es active Active
- 2011-01-24 SI SI201132101T patent/SI3494972T1/sl unknown
- 2011-01-24 NZ NZ627824A patent/NZ627824A/en unknown
- 2011-01-24 PT PT16187411T patent/PT3127542T/pt unknown
- 2011-01-24 SG SG10201707183TA patent/SG10201707183TA/en unknown
- 2011-01-24 DK DK15164931.6T patent/DK2932970T3/en active
- 2011-01-24 SI SI201131593T patent/SI3127542T1/sl unknown
- 2011-01-24 CA CA2787691A patent/CA2787691C/en active Active
- 2011-01-24 PT PT151649316T patent/PT2932970T/pt unknown
- 2011-01-24 EA EA201690872A patent/EA032868B1/ru active Protection Beyond IP Right Term
- 2011-01-24 MX MX2014014688A patent/MX367937B/es unknown
- 2011-01-24 HR HRP20240168TT patent/HRP20240168T1/hr unknown
- 2011-01-24 MX MX2014014687A patent/MX367938B/es unknown
- 2011-01-24 CN CN201510619148.8A patent/CN105311033B/zh active Active
- 2011-01-24 NZ NZ627827A patent/NZ627827A/en unknown
- 2011-01-24 RS RS20181178A patent/RS57728B1/sr unknown
- 2011-01-24 BR BR112012018670-1A patent/BR112012018670A2/pt not_active Application Discontinuation
- 2011-01-24 DK DK11737484.3T patent/DK2531027T3/en active
- 2011-01-24 FI FIEP19151897.6T patent/FI3494972T3/fi active
- 2011-01-24 SG SG10201509476RA patent/SG10201509476RA/en unknown
- 2011-01-24 LT LTEP15164931.6T patent/LT2932970T/lt unknown
- 2011-01-24 EA EA202190473A patent/EA202190473A3/ru unknown
- 2011-01-24 RS RS20150462A patent/RS54123B1/en unknown
- 2011-01-24 KR KR1020127022254A patent/KR101830715B1/ko active IP Right Grant
- 2011-01-24 EA EA201892277A patent/EA037601B1/ru active Protection Beyond IP Right Term
- 2011-01-24 ES ES15164931.6T patent/ES2670811T3/es active Active
- 2011-01-24 NO NO15164931A patent/NO2932970T3/no unknown
- 2011-01-24 KR KR1020177017713A patent/KR20170078868A/ko active Application Filing
- 2011-01-24 NZ NZ627826A patent/NZ627826A/en unknown
- 2011-01-24 KR KR1020167025050A patent/KR101883750B1/ko active IP Right Grant
- 2011-01-24 AU AU2011209788A patent/AU2011209788C1/en active Active
- 2011-01-24 WO PCT/US2011/022219 patent/WO2011094150A1/en active Application Filing
- 2011-01-24 ES ES11737484.3T patent/ES2543066T3/es active Active
- 2011-01-24 NZ NZ601319A patent/NZ601319A/en unknown
- 2011-01-24 CA CA3060290A patent/CA3060290C/en active Active
- 2011-01-24 MA MA35145A patent/MA34002B1/fr unknown
- 2011-01-24 AP AP2012006445A patent/AP3551A/xx active
- 2011-01-24 LT LTEP16187411.0T patent/LT3127542T/lt unknown
- 2011-01-24 LT LTEP19151897.6T patent/LT3494972T/lt unknown
- 2011-01-24 SI SI201130539T patent/SI2531027T1/sl unknown
- 2011-01-24 PL PL15164931T patent/PL2932970T3/pl unknown
- 2011-01-24 EA EA201290583A patent/EA025176B1/ru active Protection Beyond IP Right Term
- 2011-01-24 ME MEP-2015-106A patent/ME02182B/me unknown
- 2011-01-24 EP EP16187411.0A patent/EP3127542B1/en active Active
- 2011-01-24 PE PE2016000261A patent/PE20160180A1/es unknown
- 2011-01-24 DK DK19151897.6T patent/DK3494972T3/da active
- 2011-01-24 JP JP2012551213A patent/JP2013518107A/ja active Pending
- 2011-01-24 KR KR1020187018909A patent/KR101964923B1/ko active IP Right Grant
- 2011-01-24 EP EP19151897.6A patent/EP3494972B1/en active Active
- 2011-01-24 HU HUE16187411A patent/HUE040554T2/hu unknown
- 2011-01-24 PE PE2012001082A patent/PE20121524A1/es active IP Right Grant
- 2011-01-24 EP EP18161536.0A patent/EP3351249A1/en not_active Withdrawn
- 2011-01-24 UA UAA201209253A patent/UA105556C2/uk unknown
- 2011-01-24 HU HUE11737484A patent/HUE026849T2/en unknown
- 2011-01-24 ES ES16187411.0T patent/ES2688925T3/es active Active
- 2011-01-24 SI SI201131492T patent/SI2932970T1/en unknown
- 2011-01-24 RS RS20180667A patent/RS57323B1/sr unknown
2012
- 2012-07-18 IL IL221007A patent/IL221007A/en active IP Right Grant
- 2012-07-18 DO DO2012000205A patent/DOP2012000205A/es unknown
- 2012-07-24 ZA ZA2012/05586A patent/ZA201205586B/en unknown
- 2012-07-24 TN TNP2012000376A patent/TN2012000376A1/en unknown
- 2012-07-26 CO CO12125933A patent/CO6602152A2/es active IP Right Grant
- 2012-07-26 CL CL2012002080A patent/CL2012002080A1/es unknown
- 2012-08-13 CR CR20120423A patent/CR20120423A/es unknown
- 2012-08-14 EC ECSP12012106 patent/ECSP12012106A/es unknown
2013
- 2013-06-06 HK HK13106716.5A patent/HK1179522A1/xx not_active IP Right Cessation
- 2013-06-06 HK HK15110408.8A patent/HK1209629A1/xx unknown
- 2013-06-06 HK HK18109751.0A patent/HK1250335A1/zh unknown
2015
- 2015-05-13 US US14/710,952 patent/US20150238496A1/en not_active Abandoned
- 2015-07-14 HR HRP20150770TT patent/HRP20150770T1/hr unknown
- 2015-07-17 CY CY20151100633T patent/CY1116509T1/el unknown
- 2015-07-24 SM SM201500177T patent/SMT201500177B/xx unknown
2016
- 2016-01-28 PH PH12016500195A patent/PH12016500195A1/en unknown
- 2016-01-29 JP JP2016015242A patent/JP2016145204A/ja active Pending
- 2016-03-18 US US15/073,728 patent/US20160199379A1/en not_active Abandoned
- 2016-04-18 IL IL245182A patent/IL245182B/en active IP Right Grant
- 2016-08-01 US US15/224,865 patent/US20160339033A1/en not_active Abandoned
- 2016-08-22 JP JP2016161610A patent/JP6268386B2/ja active Active
- 2016-12-01 US US15/366,566 patent/US20170119777A1/en not_active Abandoned
- 2016-12-01 US US15/366,442 patent/US10426780B2/en active Active
2017
- 2017-04-19 US US15/490,944 patent/US20170216284A1/en not_active Abandoned
- 2017-06-13 US US15/620,859 patent/US20170281636A1/en not_active Abandoned
- 2017-12-12 US US15/838,738 patent/US20180098992A1/en not_active Abandoned
2018
- 2018-01-31 IL IL257267A patent/IL257267B/en active IP Right Grant
- 2018-03-15 US US15/922,240 patent/US20180200254A1/en not_active Abandoned
- 2018-04-05 JP JP2018072861A patent/JP2018127473A/ja active Pending
- 2018-05-23 CY CY20181100548T patent/CY1120457T1/el unknown
- 2018-05-30 HR HRP20180855TT patent/HRP20180855T1/hr unknown
- 2018-09-26 HR HRP20181531TT patent/HRP20181531T1/hr unknown
- 2018-10-15 NO NO2018036C patent/NO2018036I1/no unknown
- 2018-10-15 FR FR18C1043C patent/FR18C1043I2/fr active Active
- 2018-10-16 CY CY2018029C patent/CY2018029I2/el unknown
- 2018-10-22 LT LTPA2018013C patent/LTC2932970I2/lt unknown
- 2018-10-23 CY CY181101087T patent/CY1121040T1/el unknown
- 2018-10-26 HU HUS1800042C patent/HUS1800042I1/hu unknown
- 2018-10-31 LU LU00090C patent/LUC00090I2/en unknown
- 2018-11-26 PH PH12018502489A patent/PH12018502489A1/en unknown
2019
- 2019-06-07 JP JP2019106635A patent/JP2019167371A/ja active Pending
- 2019-06-26 IL IL267658A patent/IL267658B/en active IP Right Grant
2020
- 2020-03-31 US US16/835,733 patent/US11234985B2/en active Active
2021
- 2021-02-26 JP JP2021030306A patent/JP2021091705A/ja active Pending
- 2021-04-01 IL IL281959A patent/IL281959B/en unknown
- 2021-07-14 DO DO2021000147A patent/DOP2021000147A/es unknown
- 2021-09-08 US US17/468,794 patent/US20210401850A1/en active Pending
2022
- 2022-03-03 JP JP2022032464A patent/JP2022071126A/ja active Pending
2023
- 2023-04-04 JP JP2023060638A patent/JP2023085431A/ja active Pending

Also Published As

Publication number	Publication date
US10426780B2 (en)	2019-10-01
MX2012008774A (es)	2012-08-17
HUE037812T2 (hu)	2018-09-28
CN105311033B (zh)	2019-05-07
KR101964923B1 (ko)	2019-04-02
EA202190473A3 (ru)	2021-12-31
ES2543066T3 (es)	2015-08-14
HRP20181531T1 (hr)	2018-11-16
BR112012018670A2 (pt)	2018-02-06
CY1120457T1 (el)	2019-07-10
NZ627826A (en)	2016-01-29
SI2932970T1 (en)	2018-07-31
RS54123B1 (en)	2015-12-31
EA201690872A2 (ru)	2016-08-31
IL257267B (en)	2019-08-29
CY2018029I1 (el)	2019-07-10
PT2531027E (pt)	2015-09-16
CA3060290A1 (en)	2011-08-04
JP2013518107A (ja)	2013-05-20
IL245182B (en)	2018-04-30
US20170216284A1 (en)	2017-08-03
SI3494972T1 (sl)	2024-03-29
EP2932970B1 (en)	2018-03-21
MA34002B1 (fr)	2013-02-01
US20150238496A1 (en)	2015-08-27
EA201892277A1 (ru)	2019-03-29
PE20160180A1 (es)	2016-05-04
ZA201205586B (en)	2014-01-29
PT2932970T (pt)	2018-06-08
RS57323B1 (sr)	2018-08-31
SG182614A1 (en)	2012-08-30
HUE040554T2 (hu)	2019-03-28
IL281959A (en)	2021-05-31
SMT201500177B (it)	2015-09-07
WO2011094150A1 (en)	2011-08-04
SG10201707183TA (en)	2017-10-30
IL257267A (en)	2018-03-29
HK1179522A1 (en)	2013-10-04
TR201807704T4 (tr)	2018-06-21
JP2022071126A (ja)	2022-05-13
JP2019167371A (ja)	2019-10-03
LT2932970T (lt)	2018-06-25
NZ601319A (en)	2014-08-29
CA2967453A1 (en)	2011-08-04
CA2787691C (en)	2018-07-17
EP2932970A1 (en)	2015-10-21
ECSP12012106A (es)	2013-05-31
DK3127542T3 (en)	2018-11-12
PH12016500195B1 (en)	2016-12-05
MY188334A (en)	2021-11-30
HRP20150770T1 (hr)	2015-08-28
JP2017008087A (ja)	2017-01-12
EP2531027A1 (en)	2012-12-12
HRP20240168T1 (hr)	2024-04-26
IL221007A (en)	2016-06-30
AP3551A (en)	2016-01-18
US20160199379A1 (en)	2016-07-14
EP3127542B1 (en)	2018-08-22
IL267658B (en)	2021-04-29
NO2932970T3 (pl)	2018-08-18
US20170079982A1 (en)	2017-03-23
RS65183B1 (sr)	2024-03-29
EA201690872A3 (ru)	2016-12-30
CY2018029I2 (el)	2019-07-10
NZ627824A (en)	2016-02-26
SI3127542T1 (sl)	2018-11-30
KR20170078868A (ko)	2017-07-07
FR18C1043I2 (fr)	2019-10-11
KR20180078358A (ko)	2018-07-09
CA3003988C (en)	2020-01-07
PH12016500195A1 (en)	2016-12-05
TN2012000376A1 (en)	2014-01-30
JP2021091705A (ja)	2021-06-17
DOP2012000205A (es)	2012-10-15
ES2688925T3 (es)	2018-11-07
LUC00090I2 (pl)	2019-01-08
JP6268386B2 (ja)	2018-01-31
JP2016145204A (ja)	2016-08-12
PL3127542T3 (pl)	2019-03-29
FR18C1043I1 (pl)	2018-11-30
IL281959B (en)	2021-12-01
KR101830715B1 (ko)	2018-04-04
DK2932970T3 (en)	2018-05-28
US20200230147A1 (en)	2020-07-23
CA2787691A1 (en)	2011-08-04
SI2531027T1 (sl)	2015-08-31
NZ627827A (en)	2016-02-26
US11234985B2 (en)	2022-02-01
EP3494972B1 (en)	2023-12-13
IL221007A0 (en)	2012-09-24
KR20160111536A (ko)	2016-09-26
ES2969969T3 (es)	2024-05-23
CL2012002080A1 (es)	2012-11-30
CN102791129A (zh)	2012-11-21
ME02182B (me)	2015-10-20
ES2670811T3 (es)	2018-06-01
EP3494972A1 (en)	2019-06-12
RS57728B1 (sr)	2018-12-31
HUE026849T2 (en)	2016-08-29
HK1209629A1 (en)	2016-04-08
CA3003988A1 (en)	2011-08-04
LTPA2018013I1 (lt)	2018-11-12
EP3351249A1 (en)	2018-07-25
LTC2932970I2 (lt)	2022-04-25
CN102791129B (zh)	2015-09-30
FI3494972T3 (fi)	2024-03-01
NO2018036I1 (no)	2018-10-15
EP4316599A2 (en)	2024-02-07
LT3494972T (lt)	2024-03-12
EA037601B1 (ru)	2021-04-20
CA2967453C (en)	2018-07-17
EA032868B1 (ru)	2019-07-31
HK1250335A1 (zh)	2018-12-14
CA3060290C (en)	2022-07-12
HUS1800042I1 (hu)	2018-11-28
US20180200254A1 (en)	2018-07-19
MX356891B (es)	2018-06-19
US20160339033A1 (en)	2016-11-24
EA025176B1 (ru)	2016-11-30
PH12018502489A1 (en)	2020-06-15
CR20120423A (es)	2012-11-22
EA201290583A1 (ru)	2013-04-30
CN105311033A (zh)	2016-02-10
KR20120128640A (ko)	2012-11-27
CO6602152A2 (es)	2013-01-18
UA105556C2 (uk)	2014-05-26
US20170281636A1 (en)	2017-10-05
JP2023085431A (ja)	2023-06-20
IL267658A (en)	2019-08-29
PE20121524A1 (es)	2012-12-03
EP2531027A4 (en)	2013-07-03
US20170119777A1 (en)	2017-05-04
EA202190473A2 (ru)	2021-06-30
CY1116509T1 (el)	2017-03-15
PT3494972T (pt)	2024-02-12
AU2011209788C1 (en)	2014-08-28
IL245182A0 (en)	2016-06-30
AP2012006445A0 (en)	2012-08-31
DK3494972T3 (da)	2024-01-29
DK2531027T3 (en)	2015-07-20
US20180098992A1 (en)	2018-04-12
JP2018127473A (ja)	2018-08-16
AU2011209788A1 (en)	2012-08-16
PL2932970T3 (pl)	2018-08-31
KR101883750B1 (ko)	2018-07-31
EP2531027B1 (en)	2015-05-06
HRP20180855T1 (hr)	2018-06-29
ME03058B (me)	2019-01-20
PT3127542T (pt)	2018-11-26
EP4316599A3 (en)	2024-04-10
MX367937B (es)	2019-09-12
SG10201509476RA (en)	2015-12-30
LT3127542T (lt)	2018-11-26
US20120295898A1 (en)	2012-11-22
MX367938B (es)	2019-09-12
CY1121040T1 (el)	2019-12-11
DOP2021000147A (es)	2022-01-16
EP3127542A1 (en)	2017-02-08
AU2011209788B2 (en)	2014-02-06
US20210401850A1 (en)	2021-12-30

Publication	Publication Date	Title
HK1179522A1 (en)	2013-10-04	Therapeutic combination comprising dolutegravir, abacavir and lamivudine dolutegravirabacvir lamivudine
IL222481A0 (en)	2012-12-31	Combination therapy
GB201012175D0 (en)	2010-09-01	Procedure and mechanisms
EP2552323A4 (en)	2013-09-25	COMBINATION THERAPY
GB201005394D0 (en)	2010-05-12	Therapy
GB0905485D0 (en)	2009-05-13	Antiviral therapy
GB0916997D0 (en)	2009-11-11	Combination therapy
GB201011138D0 (en)	2010-08-18	Vaporiser
GB0907973D0 (en)	2009-06-24	Combination therapy
GB0922098D0 (en)	2010-02-03	Therapeutic use
GB0921244D0 (en)	2010-01-20	Therapy
GB0914820D0 (en)	2009-09-30	WATerian therapy
GB0903321D0 (en)	2009-04-08	Therapy
GB0903319D0 (en)	2009-04-08	Therapy
GB0903145D0 (en)	2009-04-08	Medicaments uses and methods
GB0908952D0 (en)	2009-07-01	Antiviral therapy
GB0904261D0 (en)	2009-04-22	New therapeutic use
GB0901902D0 (en)	2009-03-11	Medicament
GB0903318D0 (en)	2009-04-08	Medicament